Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MLTX
stocks logo

MLTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.973
+35.15%
--
--
-0.896
+42.22%
--
--
-0.908
+4.37%
Estimates Revision
The market is revising No Change the revenue expectations for MoonLake Immunotherapeutics (MLTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -74.77%.
EPS Estimates for FY2025
Revise Upward
up Image
+5.55%
In Past 3 Month
Stock Price
Go Down
down Image
-74.77%
In Past 3 Month
Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 15.38 USD with a low forecast of 5.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 15.38 USD with a low forecast of 5.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
5 Hold
2 Sell
Moderate Buy
Current: 14.995
sliders
Low
5.00
Averages
15.38
High
30.00
Current: 14.995
sliders
Low
5.00
Averages
15.38
High
30.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$30 -> $26
2025-11-21
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $26
2025-11-21
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on MoonLake Immunotherapeutics to $26 from $30 and keeps a Buy rating on the shares. The firm cites the Q3 results and completed equity financing for the target drop.
Goldman Sachs
Neutral
maintain
$7 -> $8
2025-11-06
Reason
Goldman Sachs
Price Target
$7 -> $8
2025-11-06
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on MoonLake Immunotherapeutics to $8 from $7 and keeps a Neutral rating on the shares.
Oppenheimer
Oppenheimer
Outperform
maintain
$25 -> $30
2025-11-06
Reason
Oppenheimer
Oppenheimer
Price Target
$25 -> $30
2025-11-06
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on MoonLake Immunotherapeutics to $30 from $25 and keeps an Outperform rating on the shares. The firm notes MoonLake reported Q3 financials and provided a business update, including results from the Phase 2 LEDA study in palmo-plantar pustulosis, interim adolescent hidradenitis suppurativa data and interim long-term efficacy data from VELA-1/VELA-2.
H.C. Wainwright
Raghuram Selvaraju
Neutral -> Buy
upgrade
$30
2025-11-03
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$30
2025-11-03
upgrade
Neutral -> Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju upgraded MoonLake Immunotherapeutics to Buy from Neutral with a $30 price target. The stock's current valuation is not appropriate given the potential of sonelokimab, the analyst tells investors in a research note. The firm says that while the regulatory pathway is yet to be determined, existing precedent "seems encouraging."
Citi
Neutral -> Sell
downgrade
$5
2025-10-29
Reason
Citi
Price Target
$5
2025-10-29
downgrade
Neutral -> Sell
Reason
Citi downgraded MoonLake Immunotherapeutics to Sell from Neutral with an unchanged price target of $5. The shares have rallied from the lows post the disappointing hidradenitis suppurativa but Citi is still cautious on the approvability and commercial competitiveness for sonelokima, the analyst tells investors in a research note. The firm also believes MoonLake has a financing overhang.
Citi
Samantha Semenkow
Buy -> Neutral
downgrade
$72 -> $5
2025-09-30
Reason
Citi
Samantha Semenkow
Price Target
$72 -> $5
2025-09-30
downgrade
Buy -> Neutral
Reason
Citi analyst Samantha Semenkow downgraded MoonLake Immunotherapeutics to Neutral from Buy with a price target of $5, down from $72. The firm cites the "disappointing" Phase 3 VELA program data for sonelokimab in hidradenitis suppurativa for the downgrade. Citi now sees "significant" regulatory risk for the drug and points out Moonlake is now facing financing challenges.
See All Ratings

Valuation Metrics

The current forward P/E ratio for MoonLake Immunotherapeutics (MLTX.O) is -3.61, compared to its 5-year average forward P/E of -20.33. For a more detailed relative valuation and DCF analysis to assess MoonLake Immunotherapeutics 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-20.33
Current PE
-3.61
Overvalued PE
-5.24
Undervalued PE
-35.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.59
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-4.41
Undervalued EV/EBITDA
-24.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MLTX News & Events

Events Timeline

(ET)
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
select
link
2025-11-05 (ET)
2025-11-05
07:47:08
MoonLake sets price for 7.14 million shares at $10.50 in underwritten offering
select
2025-11-05
07:05:36
MoonLake Immunotherapeutics Publishes Clinical Trial Results for Nanobody SLK
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
05:21 AMGlobenewswire
MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud, Claims Deadline December 15
  • Lawsuit Notification: Levi & Korsinsky LLP has informed investors in MoonLake Immunotherapeutics about a class action lawsuit due to alleged securities fraud occurring between March 2024 and September 2025, aiming to recover losses for affected investors.
  • Case Details: The complaint alleges that the defendants concealed critical information regarding their sole drug candidate SLK, including its shared molecular targets with BIMZELX, misleading investors about SLK's clinical advantages and impacting stock performance.
  • Claims Deadline: Investors who suffered losses must request to be appointed as lead plaintiff by December 15, 2025, with the opportunity to share in any recovery without needing to serve as lead plaintiff.
  • Law Firm Expertise: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has extensive experience in complex securities litigation, being ranked among the top securities litigation firms in the U.S. for seven consecutive years.
[object Object]
Preview
7.0
04:21 AMGlobenewswire
MoonLake Immunotherapeutics Faces Class Action Over Concealed Clinical Data, Stock Plummets 90%
  • Lawsuit Initiation: Hagens Berman reminds investors that the deadline to apply as lead plaintiff in the class action against MoonLake Immunotherapeutics is December 15, 2025, urging prompt action to safeguard their interests.
  • Stock Collapse: MoonLake's stock plummeted 90% from $61.99 to $6.24 on September 29, 2025, reflecting severe market skepticism regarding the authenticity of the company's clinical data.
  • Clinical Performance Controversy: The lawsuit alleges that MoonLake concealed the true clinical performance of SLK in the VELA trials, leading investors to miss critical competitive insights that could have influenced their investment decisions.
  • Investor Losses: Hagens Berman is investigating whether investors who purchased MLTX shares between March 10, 2024, and September 29, 2025, suffered significant losses due to undisclosed trial flaws, potentially entitling them to damages.
[object Object]
Preview
7.0
01:22 AMGlobenewswire
MoonLake and Others Face Class Action Lawsuits; Investors Must Note Deadlines
  • MoonLake Lawsuit: A class action lawsuit against MoonLake Immunotherapeutics alleges that during the period from March 10, 2024, to September 29, 2025, the company made materially false statements, misleading investors about its prospects, with a lead plaintiff deadline of December 15, 2025.
  • Baxter Issues: Baxter International is facing a class action lawsuit regarding systemic defects in its Novum LVP devices, which exposed patients to serious injury risks, and investors must act by December 15, 2025, to protect their rights.
  • James Hardie Allegations: A class action lawsuit against James Hardie Industries claims that from May 20, 2025, to August 18, 2025, the company failed to disclose fraudulent sales practices, with a lead plaintiff deadline of December 23, 2025.
  • Legal Consultation Advice: Investors are encouraged to contact The Law Offices of Frank R. Cruz to understand their legal rights and ensure their interests are protected in these class actions.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is MoonLake Immunotherapeutics (MLTX) stock price today?

The current price of MLTX is 14.995 USD — it has increased 12.32 % in the last trading day.

arrow icon

What is MoonLake Immunotherapeutics (MLTX)'s business?

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

arrow icon

What is the price predicton of MLTX Stock?

Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 15.38 USD with a low forecast of 5.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is MoonLake Immunotherapeutics (MLTX)'s revenue for the last quarter?

MoonLake Immunotherapeutics revenue for the last quarter amounts to -71.43M USD, increased 65.69 % YoY.

arrow icon

What is MoonLake Immunotherapeutics (MLTX)'s earnings per share (EPS) for the last quarter?

MoonLake Immunotherapeutics. EPS for the last quarter amounts to -44543000.00 USD, increased 75.32 % YoY.

arrow icon

What changes have occurred in the market's expectations for MoonLake Immunotherapeutics (MLTX)'s fundamentals?

The market is revising No Change the revenue expectations for MoonLake Immunotherapeutics (MLTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -74.77%.
arrow icon

How many employees does MoonLake Immunotherapeutics (MLTX). have?

MoonLake Immunotherapeutics (MLTX) has 100 emplpoyees as of December 05 2025.

arrow icon

What is MoonLake Immunotherapeutics (MLTX) market cap?

Today MLTX has the market capitalization of 1.08B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free